A Pilot Study of Temozolomide and 06Benzylguanine for Treatment of Newly Diagnosed High Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection

Trial Profile

A Pilot Study of Temozolomide and 06Benzylguanine for Treatment of Newly Diagnosed High Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2012

At a glance

  • Drugs Temozolomide (Primary) ; Benzylguanine
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Planned end date changed from 1 Dec 2008 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 07 Jan 2009 Status changed from recruiting to suspended due to slow patient accrual and issues with drug availability according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top